^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
12MO - Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase 3 POSEIDON study
Published date:
03/23/2023
Excerpt:
78%, 82% and 74% of pts who received T+D+CT, D+CT or CT completed 4 CT cycles. 560 pts had stable disease (SD) after cycle (C) 2. Of these, 22.9% had partial response (PR) after C4 (table). A similar trend was observed in pts with STK11m, KEAP1m or KRASm mNSCLC; in these pts, improvement appeared greatest with T+D+CT....These exploratory data support the use of 4 CT cycles, when given with T (limited course) and D (until progression), to optimise response and tumour shrinkage in pts with mNSCLC, including some harder to treat subgroups.
Trial ID:
Source:
Title:
LBA59 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Published date:
09/05/2022
Excerpt:
A trend for OS benefit with T+D+CT vs CT continued to be observed in non-squamous subgroups with mutations (m) in STK11 (Table), KEAP1 or KRAS (data will be presented)….The results of this exploratory analysis from POSEIDON, after mFU of ∼4 y, demonstrate the durable long-term OS benefit of adding a limited course of T to D and 4 cycles of CT. These data support the use of this regimen as a 1L treatment option for pts with mNSCLC, including harder-to-treat mutational subgroups such as STK11m, KEAP1m or KRASm.
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
Excerpt:
...- Participants must have tumors with STK11 or KEAP1 or KRAS mutations....
Trial ID:
Source:
Title:
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
Excerpt:
...When a patient with non-squamous NSCLC has a KRAS mutation, further testing for EGFR and EML4-ALK is...
Trial ID:
